JP4945101B2 - クレアチニン及び尿酸吸着用経口投与吸着剤 - Google Patents
クレアチニン及び尿酸吸着用経口投与吸着剤 Download PDFInfo
- Publication number
- JP4945101B2 JP4945101B2 JP2005238798A JP2005238798A JP4945101B2 JP 4945101 B2 JP4945101 B2 JP 4945101B2 JP 2005238798 A JP2005238798 A JP 2005238798A JP 2005238798 A JP2005238798 A JP 2005238798A JP 4945101 B2 JP4945101 B2 JP 4945101B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- creatinine
- clay
- uric acid
- orally administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 title claims description 58
- 229940109239 creatinine Drugs 0.000 title claims description 29
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims description 25
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims description 25
- 229940116269 uric acid Drugs 0.000 title claims description 25
- 239000003463 adsorbent Substances 0.000 title claims description 22
- 238000001179 sorption measurement Methods 0.000 title claims description 22
- 239000004927 clay Substances 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000005341 cation exchange Methods 0.000 claims description 9
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 9
- 150000002500 ions Chemical class 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 3
- 238000007561 laser diffraction method Methods 0.000 claims description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- 239000010410 layer Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- -1 nitrogen-containing compound Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 229910052901 montmorillonite Inorganic materials 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002734 clay mineral Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229910004283 SiO 4 Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940124355 agent for urolithiasis Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
EH=(B−A)×104
式中、Aは、前記懸濁液での水素イオン濃度(gイオン/L)であり、
Bは、該酸性白土を1wt%食塩水に5(w/v)%濃度で分散させたとき
の懸濁液の水素イオン濃度(gイオン/L)である、
で算出されるプロトン放出能EHが2.0以上であることを特徴とするクレアチニン及び尿酸吸着用経口投与吸着剤が提供される。
(1)前記酸性白土の粒子は、レーザー回折法で測定して3乃至100μmの体積平均粒径(D50)を有していること、
(2)前記酸性白土の粒子100重量部に対して可食性有機酸を0.01乃至20重量部含有してなること、
(3)前記酸性白土の粒子の成形体からなり、該成形体の長径が0.1乃至10.0mmの範囲にあり、且つ長径/短径比が1乃至10であること、
が好ましい。
EH=(B−A)×104
式中、Aは、前記懸濁液での水素イオン濃度(gイオン/L)であり、
Bは、該酸性白土を1wt%食塩水に5(w/v)%濃度で分散させたとき
の懸濁液の水素イオン濃度(gイオン/L)である、
で算出される。
R2O/SiO2=0.1×10−2 乃至1.5×10−2
(特に、Na2O/SiO2=0.3×10−2 乃至1.0×10−2)
且つ
M2O/SiO2=4.5×10−2 乃至10.5×10−2
可食性有機酸としては、食品添加物として許容されているカルボン酸、オキシカルボン酸が好ましい。具体的には、氷酢酸、プロピオン酸、酪酸、安息香酸、シュウ酸、コハク酸、アジピン酸、乳酸、リンゴ酸、クエン酸、グルコン酸、フマル酸が使用できる。
また、必要により上記の可食性有機酸塩も使用することができ、塩としては、カリウム、ナトリウム、アンモニウムの塩が使用できる。
また、家畜類やヒトに対して経口投与するために、前記粘土粒子の成形体は、該成形体の長径が0.1乃至10.0mmの範囲にあり、且つ長径/短径比が1乃至10、好ましくは1乃至3であることが好ましく、その使用方法としては、それ単独で、または他の薬剤や飼料と混合してもよい。
日本ベントナイト工業会標準試験方法により、測定を行った。
100mLビーカーに脱イオン水75gをとり、試料5gを加え、5分間煮沸する。冷却後、懸濁液の全量を少量の脱イオン水とともに共栓付メスシリンダーに移し容れ、さらに少量の脱イオン水を加えて全容量を100mLとしてよく振り混ぜる。該懸濁液の3分間静置後のpHを測定し、水素イオン濃度〔A〕(gイオン/L)を計算し求める。さらに、脱イオン水に替えて1%食塩水を用いて同様の操作を行い、1%食塩水における水素イオン濃度〔B〕(gイオン/L)を計算する。求められた水素イオン濃度(gイオン/L)の差(B−A)に104を乗じて算出されるEHをプロトン放出能とした。
EH=(B−A)×104
Jaff法により以下の方法で測定を行った。
プラスチック製遠沈管(12mL)に所定量の試料を精秤し、所定濃度のクレアチニン溶液(クレアチニン濃度:10mg/100mL)5mLを加え、室温にて10分間かき混ぜた後、2500rpm(r=85mm)で15分間遠心分離する。上清2mLを新しい遠沈管(12mL)に取り、それにピクリン酸溶液(22mmol/L)と水酸化ナトリウム溶液(0.75mol/L)を各1mL加えてかき混ぜ、30℃にコントロールした水槽で20分間放置する。該液を、さらに2500rpmで10分間遠心分離し、上清を試料液として、分光光度計により520nmにおける吸光度を測定する。あらかじめ同様の操作にて作成した検量線より、該液のクレアチニン濃度〔C〕(mg/100mL)を計算し、試料のクレアチニン吸着率(%)を次式により求める。
クレアチニン吸着率=(10−C)÷10×100=(10−C)×10
紫外部吸光光度法により、以下のようにして測定を行った。
プラスチック製遠沈管(12mL)に所定量の試料を精秤し、所定濃度の尿酸溶液(尿酸濃度:5mg/100mL、)10mLを加え、室温にて10分間かき混ぜた後、2500rpm(r=85mm)で15分間遠心分離する。上清を試料液として、紫外分光光度計により284nmにおける吸光度を測定する。あらかじめ同様の操作にて作成した検量線より該液の尿酸濃度〔U〕(mg/100mL)を計算し、試料の尿酸吸着率(%)を次式により求める。
尿酸吸着率=[(5−U)÷5]×100=(5−U)×20
表1に示す各試料を10mm程度に粗砕し、それの1kgをファインデスクペレッター(不二パウダル社製)で1mmの円柱状に成形する。それを150℃で6時間乾燥する。乾燥品をスピードミル(昭和エンジニアリング社製)で粉砕し粒状品を得た。
各実施例の内容、陽イオン交換能、プロトン放出能およびクレアチニン吸着率と尿酸吸着率を表1に示した。
表1に示す各粉末試料1kgを10リットルのプラスチック容器に取り、0.05NのHCl溶液5リットルを加え、室温にて1時間かき混ぜた後ろ過し、さらに20リットルの清水で洗浄する。それを水分約30%まで乾燥し、ファインデスクペレッター(不二パウダル社製)で1mmの円柱状に成形する。それを150℃で6時間乾燥する。乾燥品をスピードミル(昭和エンジニアリング社製)で粉砕し粒状品を得た。
各実施例の内容、陽イオン交換能、プロトン放出能およびクレアチニン吸着率と尿酸吸着率を表1に示した。
表1に示す各試料の粉末品を用いた。
各比較例の内容、陽イオン交換能、プロトン放出能およびクレアチニン吸着率と尿酸吸着率を表2に示した。
粉末試料100gを1リットルのビーカーに取り、0.05NのHCl溶液500mLを加え、室温にて1時間かき混ぜた後ろ過し、さらに2リットルの清水で洗浄する。それを150℃で6時間乾燥後、乳鉢で粉砕し粉末を得た。
内容と陽イオン交換能、プロトン放出能およびクレアチニン吸着率と尿酸吸着率を表2に示した。
Claims (4)
- 陽イオン交換能が50ミリイクイバレント/100g以上の酸性白土の粒子からなる含窒素化合物用経口投与吸着剤であって、該粒子が、脱イオン水に5(w/v)%濃度で分散させた懸濁液でのpH(25℃)が5.0以下であり、且つ下記式:
EH=(B−A)×104
式中、Aは、前記懸濁液での水素イオン濃度(gイオン/L)であり、
Bは、該酸性白土を1wt%食塩水に5(w/v)%濃度で分散させたとき
の懸濁液の水素イオン濃度(gイオン/L)である、
で算出されるプロトン放出能EHが2.0以上であることを特徴とするクレアチニン及び尿酸吸着用経口投与吸着剤。 - 前記酸性白土の粒子は、レーザー回折法で測定して3乃至100μmの体積平均粒径(D50)を有している請求項1に記載のクレアチニン及び尿酸吸着用経口投与吸着剤。
- 前記酸性白土の粒子100重量部に対して可食性有機酸を0.01乃至20重量部含有してなる請求項1又は2に記載のクレアチニン及び尿酸吸着用経口投与吸着剤。
- 前記酸性白土の粒子の成形体からなり、該成形体の長径が0.1乃至10.0mmの範囲にあり、且つ長径/短径比が1乃至10である請求項1乃至3のいずれかに記載のクレアチニン及び尿酸吸着用経口投与吸着剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005238798A JP4945101B2 (ja) | 2004-08-27 | 2005-08-19 | クレアチニン及び尿酸吸着用経口投与吸着剤 |
US11/424,174 US20060275508A1 (en) | 2004-08-27 | 2006-06-14 | Orally Administered Adsorbent Having Excellent Property for Adsorbing Nitrogen-Containing Compounds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004248591 | 2004-08-27 | ||
JP2004248591 | 2004-08-27 | ||
JP2005238798A JP4945101B2 (ja) | 2004-08-27 | 2005-08-19 | クレアチニン及び尿酸吸着用経口投与吸着剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006089466A JP2006089466A (ja) | 2006-04-06 |
JP4945101B2 true JP4945101B2 (ja) | 2012-06-06 |
Family
ID=36230777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005238798A Active JP4945101B2 (ja) | 2004-08-27 | 2005-08-19 | クレアチニン及び尿酸吸着用経口投与吸着剤 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20060275508A1 (ja) |
JP (1) | JP4945101B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5146643B2 (ja) * | 2007-06-08 | 2013-02-20 | 黒崎白土工業株式会社 | 含窒素化合物の吸着特性に優れた経口投与吸着剤及びその製造方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5563652A (en) * | 1978-11-09 | 1980-05-13 | Kyowa Kagaku Kogyo Kk | Blood purifying method and purifying agent |
US4293445A (en) * | 1980-01-03 | 1981-10-06 | Sumitomo Chemical Company, Limited | Method for production of molded product containing titanium oxide |
JPS6158543A (ja) * | 1984-08-31 | 1986-03-25 | Yasuichi Kobayashi | 家畜飼料添加物とその製造方法 |
JPS62145022A (ja) * | 1985-12-18 | 1987-06-29 | Sofuto Shirika Kk | 食中毒症用薬剤 |
US4693639A (en) * | 1986-06-25 | 1987-09-15 | Halliburton Company | Clay stabilizing agent preparation and use |
US5179955A (en) * | 1991-02-22 | 1993-01-19 | Molecular Biosystems, Inc. | Method of abdominal ultrasound imaging |
JPH05244879A (ja) * | 1992-03-09 | 1993-09-24 | Kazuo Yanai | 鶏用飼料 |
US5639492A (en) * | 1995-01-13 | 1997-06-17 | Amcol International Corporation | Method and composition for achieving animal weight gain with mycotoxin-contaminated animal food |
RU2125460C1 (ru) * | 1997-11-17 | 1999-01-27 | Закрытое акционерное общество научно-производственная фирма "Новь" | Биостимулирующее средство |
-
2005
- 2005-08-19 JP JP2005238798A patent/JP4945101B2/ja active Active
-
2006
- 2006-06-14 US US11/424,174 patent/US20060275508A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060275508A1 (en) | 2006-12-07 |
JP2006089466A (ja) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2271336C2 (ru) | Композиции для обработки воды | |
US8883216B2 (en) | Methods and ceramic nanoparticle compositions for heavy metal removal and for oral delivery of desirable agents | |
US20040105895A1 (en) | Monovalent-selective cation exchangers as oral sorbent therapy | |
US6461535B1 (en) | Composition for arsenic removal from ground water | |
JP2008516971A (ja) | 錠剤による負荷が軽減されるリン酸塩結合剤 | |
JPS6229368B2 (ja) | ||
WO2010028215A1 (en) | Antimicrobial fish and shrimp feed | |
CN101808947A (zh) | 用于膜电解的方法和由其获得的产物的用途 | |
KR20040030617A (ko) | 오오시스트의 파괴 방법 | |
JP4945101B2 (ja) | クレアチニン及び尿酸吸着用経口投与吸着剤 | |
KR20130095268A (ko) | 경구 투여용 흡착제 및 그 제조 방법 그리고 그것을 사용한 약제 | |
JP5146643B2 (ja) | 含窒素化合物の吸着特性に優れた経口投与吸着剤及びその製造方法 | |
JP2006070022A (ja) | シクロデキストリン含有薬剤または食品添加剤 | |
CN102844077A (zh) | 一种用于中和胃酸的固体药物组合物 | |
EP2204178A1 (en) | Laxative agent | |
US20120100226A1 (en) | Preventive remedial therapeutic agent for phosphorus impairment, oral agent for adsorbing phosphate ion contained in food, beverage and chemical, and process for producing them | |
US9585913B2 (en) | Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy | |
JP6280636B2 (ja) | カリウムの低減と慢性腎臓病及び/または慢性心臓病の治療のための微多孔性ケイ酸ジルコニウム及び利尿剤 | |
WO2007107434A1 (en) | Water purification tablet and process | |
JP2011088870A5 (ja) | ||
TWI444190B (zh) | 潰瘍治療劑 | |
JPWO2005039312A1 (ja) | 食品 | |
JP2981574B2 (ja) | リン酸イオン吸着剤 | |
JP4602005B2 (ja) | 家畜、家禽用抗菌、防臭剤 | |
Fatima et al. | Conceptual Importance of Acidifiers, Antacids and Cathartics for its Significance in Pharmaceuticals-A Brief Review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111006 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120117 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120221 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120305 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4945101 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150309 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |